Review Article

State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

Cecilia Trucchi,1 Andrea Orsi,1,2 Cristiano Alicino,1 Laura Sticchi,1,2 Giancarlo Icardi,1,2 and Filippo Ansaldi1,2

1Department of Health Sciences, University of Genoa, 16132 Genoa, Italy
2IRCCS AOU San Martino-IST, 16132 Genoa, Italy

Correspondence should be addressed to Cecilia Trucchi; cecilia.trucchi@unige.it

Received 30 June 2016; Revised 9 September 2016; Accepted 20 September 2016

Academic Editor: Roberta A. Diotti

Copyright © 2016 Cecilia Trucchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatitis C virus (HCV) still represents a major public health threat, with a dramatic burden from both epidemiological and clinical points of view. New generation of direct-acting antiviral agents (DAAs) has been recently introduced in clinical practice promising to cure HCV and to overcome the issues related to the interferon-based therapies. However, the emergence of drug resistance and the suboptimal activity of DAAs therapies against diverse HCV genotypes have been observed, determining treatment failure and hampering an effective control of HCV spread worldwide. Moreover, these treatments remain poorly accessible, particularly in low-income countries. Finally, effective screening strategy is crucial to early identifying and treating all HCV chronically infected patients. For all these reasons, even though new drugs may contribute to impacting HCV spread worldwide a preventive HCV vaccine remains a cornerstone in the road to significantly reduce the HCV spread globally, with the ultimate goal of its eradication. Advances in molecular vaccinology, together with a strong financial, political, and societal support, will enable reaching this fundamental success in the coming years. In this comprehensive review, the state of the art about these major topics in the fight against HCV and the future of research in these fields are discussed.

1. Introduction

Among infectious diseases, hepatitis C virus (HCV) still represents a major public health threat, with a dramatic burden from both epidemiological and clinical points of view. Chronically infected individuals are estimated to reach 150–170 million worldwide and estimates of incidence, performed in the United States by the Center for disease control and prevention (CDC), reported nearly 30,000 new HCV infections in 2013 [1, 2].

Although HCV infection is characterized by a global diffusion, its prevalence greatly differs according to geographic area [3, 4]. Central Asia, Eastern Europe, the Midwest of North Africa region, and Central and Western Sub-Saharan Africa present high HCV prevalence rates, with figures ranging between 3.1% and 5.4%; regions with intermediate prevalence rates are Southern Sub-Saharan Africa, Central Europe, Australia, and Latin America, with values between 1% and 1.4%; low prevalence is found in Oceania (0.1%), Caribbean (0.8%), and Western Europe (0.9%) [3].

After acute infection, 75% of infected subjects become chronically infected and approximately 20% of this population develops liver cirrhosis during the two decades after infection if left untreated [5, 6]. However, since in most cases acute infection is asymptomatic, most HCV infections are clinically silent until the disease reaches a late stage: HCV was estimated to cause 25% of all cases of liver cirrhosis and cancer worldwide and to account for more than 500,000 deaths per year [7].

In recent years, substantial advances have been made to understand HCV biology and to develop a new generation of effective direct-acting antiviral agents (DAAs) able to...
cure HCV. However, several challenges hamper an effective control of HCV spread worldwide. In fact, the emergence of drug resistance and the suboptimal activity of these therapies against diverse HCV genotypes have been observed and have been associated with treatment failure. Moreover, the high costs of these drugs and the high prevalence of HCV-infected individuals, especially in low-income countries, jeopardized the affordability for the healthcare system to treat all infected patients in developed countries and, even more, in developing countries [8, 9]. Finally, effective screening strategy is required to early identify and treat all HCV chronically infected patients thus limiting the infection transmission risk as well as the progression to cirrhosis or hepatocellular carcinoma and reducing the healthcare costs [10, 11]. For all these reasons, a preventive HCV vaccine remains a cornerstone in the road to significantly reduce the HCV spread globally.

This comprehensive review summarized the state of the art about three major unresolved issues in the fight against HCV: which are the perspectives for the universal screening of HCV? Do we need DAAs resistance testing in the future? How close is an effective preventive HCV vaccine?

2. Which Are the Perspectives for the Universal Screening of HCV?

The rate of underdetection of HCV infection is still relevant because of clinical, educational, technical, organizational, and economic issues. In fact, recent estimates suggest that most of people with HCV remain undiagnosed or unaware of their HCV infection [12, 13].

Another criticism is represented by the difficulty in early diagnosing HCV infection. Indeed, few people are diagnosed during the acute phase because it is usually asymptomatic [14]. Furthermore, the 55–85% of persons who do not spontaneously clear the virus within 6 months develop chronic infection and remain asymptomatic for decades after infection, during which infection may be transmitted to other persons. Chronically infected patients usually become symptomatic when the HCV-induced liver damage is advanced and the therapy may be contraindicated [14]. The risk of late diagnosis is associated also with the limited access to HCV testing in many countries where HCV prevalence is high, such as African and Central-East Asian countries [15].

Therefore, it is crucial to implement the most sensitive and specific approaches to diagnose chronic HCV infection before the development of liver damage and to assure the linkage to care of infected patients [16].

2.1. Screening Tests for HCV Infection. A testing strategy for HCV infections characterized by high sensitivity and specificity should be established.

The WHO recommends offering the HCV serology test to individuals belonging to population with high HCV prevalence or who have a history of HCV risk exposure/behavior [14]. Given that HCV antibodies can be detected two months following the infection and are also detectable in patients who have cleared the virus, a positive result for antibodies against viral proteins (anti-HCV) should be followed by a nucleic acid testing using a reverse transcription polymerase chain reaction (RT-PCR) for the detection of HCV RNA and to confirm chronic HCV infection [14, 17]. Molecular testing is more technically demanding than the serology but it guarantees positive results already after few weeks following the exposure.

Among serologic screening test, the enzyme immunoassays (EIAs) are generally used [18]. EIAs are characterized by high sensitivity and specificity, fast processing, high reliability, relatively low costs, and the possibility of automation, useful for large volume testing [19–21]. In particular, the third generation test of EIAs is available [22] and has an estimated sensitivity and specificity of 98.9% and 100%, respectively, in patients with chronic liver disease [23]. However, the serological window period of this assay is generally more than 40 days [24] and it should not be used in infants younger than 18 months because of the possible reaction with maternal antibody [25].

Recently, the possibility of a single serologic assay for the detection of HCV active infection has become available. This test is based on the identification of the HCV core antigen (HCVAg) that is detectable in acute infection almost at the same time as HCV RNA [26] and persists during all phases of infection [27], indicating its potential use as a less expensive technique than molecular assays.

In consideration of improving the testing access, some countries such as US [28] and France [29] validated the use of Point of Care (POC) not only for HIV but also for HCV infection screening. Although rapid tests have lower sensitivity than standard serological tests and require a specific organization to allow traceability of results, they are characterized by relevant advantages such as the minimal equipment required, the ease of obtaining the samples and of performing the test, and the short time to obtain the results [30, 31]. However a recent meta-analysis that compared seven POC demonstrated that OraQuick had the highest test sensitivity and specificity and showed better performance than a third generation enzyme immunoassay in seroconversion panels [32]. The availability of POC rapid tests represents an opportunity to broaden the screening strategies to people outside the healthcare structures [11], thus helping the achievement of individuals at highest risk, such as people who inject drugs, the homeless, and the incarcerated.

2.2. Identifying Patients with HCV. The variability of the risk factors and history of behaviors linked to HCV infection, depending on the geographical setting and population studied, make the identification of the target population for screening policies challenging worldwide.

In many high-income countries HCV screening recommendations are targeted to subjects with a history of HCV risk exposure or behavior and certain medical conditions and who belong to a population of known high HCV prevalence [33, 34]. In particular, at risk populations include those who have received medical procedures such as hemodialysis or dental interventions in healthcare facilities with inadequate infection control practices, persons who have received blood transfusions, an organ transplant, or tissue graft prior to the time when HCV serological testing of blood

Journal of Immunology Research
donors was introduced or in countries where it is not routinely performed, subjects who inject drugs or who have used intranasal drugs, persons who have received tattoos, body piercing, or scarification procedures in settings where infection control practices are substandard, children born to mothers infected with HCV, healthcare workers who sustained a needle stick or mucosal splash exposure from a patient with HCV, and patients with HIV infection who have unprotected sex with men, prisoners, and previously incarcerated persons (Class I, Level B recommendation) [10, 16, 35].

In 2012, the Center of Disease Control and Prevention (CDC) and the US Preventive Services Task Force (USPSTF) extended the HCV screening recommendation to all persons born from 1945 through 1965, without prior ascertainment of HCV risk factors (Class I, Level B recommendation) [35–37]. The rationale of this recommendation is based on the evidence that the risk-based strategy alone failed to identify more than 50% of HCV infections because of healthcare provider limitations in ascertaining risk factor information [38, 39] and due to patients’ underreporting of their own risk behaviors (e.g., injecting drug use) or exposure (e.g., iatrogenic infection). Furthermore, persons in the 1945 to 1965 birth cohort accounted for about 75% of all HCV infections, with a five times higher prevalence (3.25%) than other persons [10, 37]. A recent retrospective review demonstrated that 68% of persons with HCV infection would have been screened through a birth cohort approach testing, while just 27% would have been identified with the risk-based strategy [40]. The cost-effectiveness of one-time birth cohort testing is comparable to that of current risk-based screening strategies [36]. Nevertheless, the implementation birth cohort screening is challenging [10]. The inclusion of queries and reminder flags among the electronic medical record (EMR) could sensitize physicians [41]. However, various types of EMR exist in USA and many reminders requiring time to be addressed are triggered during each visit [10]. Furthermore, the identification of the best setting to implement the screening of birth cohort represents a further issue. Available evidences suggest that the hospital setting allows reaching better results than the outpatients’ visits such as routine colon cancer screening colonoscopy [42–45].

In Japan, where the overall prevalence of HCV infection is comparable with the USA, but different transmission patterns determined different age-specific prevalence, the national screening for HCV in both the high-risk group and the general population from ages 40 to 70 started at 2002 and has demonstrated to be cost-effective in containing the epidemic [46, 47].

In Europe, accurate estimates of HCV incidence and prevalence are not available; however prevalence estimates vary from 0.4% (Austria, Cyprus, Germany, Denmark, France, and United Kingdom) to 1.5% (Israel and Italy) in Western Europe and from 0.7% (Czech Republic) to 4.5% (Moldova) in Central and Eastern Europe [46]. HCV screening programs are implemented for organ and blood donors as well as for patients undergoing hemodialysis, but not for risk groups such as injecting drug users, who currently represent the leading cause of transmission across Europe [48, 49]. Furthermore, the rising issue of fluid immigration patterns from countries with high prevalence such as Egypt has not been addressed yet [50].

Developing nations, where the population-based prevalence of anti-HCV may reach as high as 11% (Mongolia) to 15% (Egypt), are less likely to be able to afford screening [46]. Many of these countries are afflicted by political and social unrest that may influence risk factors of HCV spread, such as trauma, use of intravenous drugs, poor water and electric supply, overcrowding, and lack of financial resources and infrastructure [46].

Considering the existing barriers that limit the implementation of screening strategies such as low provider knowledge about HCV and its related risk factors [13, 51–54], the WHO Guidelines Development Group conducted a systematic review to find the evidences about the most effective strategies to promote HCV testing [16]. Sensitizing the practitioners about the importance of early HCV diagnosis through in-service training sessions or mailed information, provision of additional clinic staff, routine offer of testing to all patients, or placing reminders in medical records resulted more effectively in increasing uptake of testing, detecting HCV antibody-positive cases, and the number of attendances and referral to specialist care than media-/information-based targeted approaches (e.g., invitations to information sessions for care providers, leaflets, and posters).

2.3. Recommendations for Frequency of HCV Screening Testing. CDC and the US Preventive Services Task Force (USPSTF) recommend a one-time HCV test in asymptomatic persons belonging to the 1945 to 1965 birth cohort and subjects with exposures, behaviors, and conditions that increase risk for HCV infection.

As regards the correct periodicity of testing persons at risk for ongoing exposure to HCV, evidence is lacking. Thus, physicians should determine the frequency of testing on the basis of the risk of reinfection. Owing to the high incidence of HCV infection among HIV-infected men who have unprotected sex with men and subjects who inject drugs [55–60], the HCV Guidance by the Infectious Diseases Society of America (IDSA) and the American Association for the study of liver diseases (AASLD) recommended that at least annual HCV testing is in these subgroups [35].

2.4. Linkage to Care. In order to enter the patients in the cascade of care and thus provide them with the so-called “continuum of care,” the detection of HCV-infected patients should be followed by linkage to care via a physician referral with expertise in evaluation and treatment HCV infection [10, 61]. However, available evidences show that many gaps between the HCV diagnosis and care cascade still exist [62, 63].

These gaps may be both patient- and practitioner-related. The most common patient-related barriers to treatment initiation include contraindications because of the presence of comorbidities, lack of acceptance, and access of treatment, due to often asymptomatic course of the infection, long treatment duration and possible adverse reactions of the treatment, high cost, and distance to specialist [64–66]. In
Table 1: Direct-acting antivirals (DDAs) approved for HCV treatment or investigated in clinical trials (updated in September 2016).

| Class                        | Generation       | Approved substances (developing company)                                                                 | Substances currently tested in clinical trials (developing company) [phase of development] |
|------------------------------|------------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| NS3/4A protease inhibitors   | First generation | Telaprevir (Janssen, Mitsubishi) Boceprevir (Merck) Simeprevir (Janssen) Paritaprevir (AbbVie) Asunaprevir (Bristol-Myers Squibb) Vaniprevir (Merck) | ABT-493 (AbbVie) [Phase 3] GS-9857 (Gilead Sciences) [Phase 3] |
|                              | Second generation| Grazoprevir (Merck)                                                                                      |                                                                                               |
| NS5A inhibitors              | First generation | Daclatasvir (Bristol-Myers Squibb) Ledipasvir (Gilead Sciences) Ombitasvir (AbbVie) Elbasvir (Merck) Velpatasvir (Gilead Sciences) | Odalasvir (Janssen) [Phase 2] Ravidasvir (Presidio) [Phase 2/3] |
|                              | Second generation|                                                                                                          | ABT-530 (AbbVie) [Phase 3] MK-8408 (Merck) [Phase 2]                                             |
| Nucleotide analogue inhibitors of NS5B RNA-dependent RNA polymerase | First generation | Sofosbuvir (Gilead Sciences)                                                                             | MK-3682 (Merck) [Phase 2] AL-335 (Janssen) [Phase 2]                                             |
| Nonnucleoside inhibitors of NS5B RNA-dependent RNA polymerase | Palm-1 inhibitors | Dasabuvir (AbbVie)                                                                                       |                                                                                               |

particular, the frequency and the severity of side effects related to pegylated interferon and ribavirin (PEG-INF/RBV) combination represent primary factors affecting both the initiation of therapy and its continuation. The tolerability of HCV therapy remained low also with the addition of first generation DAAs (telaprevir and boceprevir) to the abovementioned therapeutic regimen [66]. The availability of new generation DAAs has improved the tolerability of the antiviral therapy [67].

Moreover, the linkage to care is critical among patients coinfected with HIV [68, 69], those with underlying psychiatric and substance use disorders, and those with social instabilities such as homelessness and incarceration [70].

General practitioner-related barriers include lack of expertise in HCV treatment, lack of specialty referral resources, resistance to treating persons currently using illicit drugs or alcohol, and concern about cost of HCV treatment [71–73].

Evidence-based interventions to address linkage to care have been summarized by Meyer JP and colleagues [61] and by the HCV Guidance by the Infectious Diseases Society of America (IDSA) and the American Association for the study of liver diseases (AASLD) recommended that at least annual HCV testing is in these subgroups [35].

These interventions include the integration of HCV screening, evaluation, and treatment center with other medical or social services, such as correctional facilities and programs providing needle exchange, substance abuse treatment, and methadone maintenance [74–76]. Multidisciplinary case management and social support have been demonstrated to facilitate the efficacious treatment of HCV-infected patients with psychiatric illness or substance use [77].

In order to address lack of access to specialists, models involving close collaboration between primary care practitioners and subspecialists also through telemedicine and multidisciplinary networks of specialists have been implemented [65, 78, 79]. Furthermore, the decreased duration and better safety profile of current HCV therapy may increase the number of mid-level practitioners and primary care physicians able to appropriately manage and treat HCV infection [35].

Additional strategies for improving linkage to and retention in care could be the use of patient navigators or care coordinators [80, 81]; however, the efficacy and effectiveness assessment of these interventions is still ongoing. The extension of best and new strategies for linkage to HCV care is essential to optimize the impact of HCV treatment.

3. Do We Need DAAs Resistance Testing in the Future?

Treatment of chronic hepatitis C has rapidly evolved from PEG-INF/RBV to more potent highly effective DAAs combination therapies. In particular, DAAs act on key stages of the HCV lifecycle and are classified on the basis of their molecular target and mechanism of action [82]. Four categories of DAAs are currently available: NS3/4A protease inhibitors, NS5A inhibitors, nucleotide analogue inhibitors of NS5B RNA-dependent RNA polymerase (RdRp), and nonnucleoside inhibitors of RdRp. Table 1 summarizes DAAs approved for HCV treatment. DAAs combination with other
Table 2: Recommended regimen for the treatment of HCV with direct-acting antivirals-based combination therapies.

| Genotype | Presence of cirrhosis | Recommended regimen | Alternative regimen | Strength of recommendation | Quality of evidence |
|----------|-----------------------|---------------------|---------------------|---------------------------|---------------------|
| 1a       | Without cirrhosis     | DCV + SOF (12 weeks) | SMV + SOF (12 weeks) | Strong                    | Moderate            |
|          |                      | LDV + SOF (12 weeks) | OBV + PTV/r + DSV + R (12 weeks) |                      |                     |
|          | With cirrhosis        | DCV + SOF (24 weeks) | SMV + SOF (24 weeks) | Strong                    | Moderate            |
|          |                      | DCV + SOF + R (12 weeks) | SMV + SOF + R (12 weeks) |                      |                     |
|          |                      | LDV + SOF (24 weeks) | OBV + PTV/r + DSV + R (24 weeks) |                      |                     |
|          |                      | LDV + SOF + R (12 weeks) | SMV + SOF + R (12 weeks) | Strong                    | Moderate            |
|          | Without cirrhosis     | DCV + SOF (12 weeks) | SMV + SOF (12 weeks) | Strong                    | Moderate            |
|          |                      | LDV + SOF (12 weeks) | OBV + PTV/r + DSV (12 weeks) |                      |                     |
|          | With cirrhosis        | DCV + SOF (12 weeks) | SMV + SOF (24 weeks) | Strong                    | Moderate            |
|          |                      | LDV + SOF (12 weeks) | SMV + SOF + R (12 weeks) |                      |                     |
|          |                      | LDV + SOF + R (12 weeks) | OBV + PTV/r + DSV + R (12 weeks) |                      |                     |
| 2        | Without cirrhosis     | SOF + R (12 weeks)  | DCV + SOF (12 weeks) | Strong                    | Low                 |
|          | With cirrhosis        | SOF + R (16 weeks)  | DCV + SOF (12 weeks) | Strong                    | Low                 |
| 3        | Without cirrhosis     | DCV + SOF (12 weeks) | SOF + PegIFN + R (12 weeks) | Strong                    | Low                 |
|          | With cirrhosis        | DCV + SOF + R (24 weeks) | SOF + PegIFN + R (12 weeks) | Strong                    | Low                 |
|          |                      | LDV + SOF (12 weeks) | SMV + SOF (12 weeks) | Strong                    | Moderate            |
|          |                      | SMV + SOF (12 weeks) | OBV + PTV/r + R (12 weeks) |                      |                     |
| 4        | With cirrhosis        | DCV + SOF (24 weeks) | SMV + SOF (24 weeks) | Strong                    | Moderate            |
|          |                      | DCV + SOF + R (12 weeks) | SMV + SOF + R (12 weeks) |                      |                     |
|          |                      | LDV + SOF (24 weeks) | OBV + PTV/r + R (24 weeks) |                      |                     |
|          | Without cirrhosis     | LDV + SOF (12 weeks) | SOF + PegIFN + R (12 weeks) | Strong                    | Low                 |
| 5        | With cirrhosis        | LDV + SOF (24 weeks) | SOF + PegIFN + R (12 weeks) | Strong                    | Low                 |
|          |                      | LDV + SOF + R (12 weeks) | SOF + PegIFN + R (12 weeks) | Strong                    | Low                 |
| 6        | Without cirrhosis     | LDV + SOF (12 weeks) | SOF + PegIFN + R (12 weeks) | Strong                    | Low                 |
|          | With cirrhosis        | LDV + SOF (24 weeks) | SOF + PegIFN + R (12 weeks) | Strong                    | Low                 |
|          |                      | LDV + SOF + R (12 weeks) | SOF + PegIFN + R (12 weeks) | Strong                    | Low                 |

DCV: daclatasvir; LDV: ledipasvir; SMV: simeprevir; SOF: sofosbuvir; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; R: ribavirin; r: ritonavir; PegIFN: pegylated interferon.

* Treatment may be shortened to 8 weeks in treatment-naive persons without cirrhosis if their baseline HCV RNA level is below 6 million (6.8 log) IU/mL. The duration of treatment should be shortened with caution.

If platelet count <75 × 10^3/μL, then 24 weeks’ treatment with ribavirin should be given.

If positive for the Q80K variant, a simeprevir/sofosbuvir regimen should not be chosen.

DAAs and/or ribavirin has been widely investigated in clinical trials and current recommendation by the World Health Organization (WHO) for the treatment of HCV with DAAs-based combination therapies is outlined in Table 2 [16]. During 2016, two novel DAAs combinations, grazoprevir/elbasvir and sofosbuvir/velpatasvir, have been licensed in US and Europe, and others are currently under evaluation in phases II and III clinical trials and may be available in the coming months [83].

The efficacy of treatment containing DAAs is very high in terms of sustained virological response (SVR); nonetheless 10–15% of therapeutic failure is observed in clinical practice, mainly associated with the selection of DAAs-resistant viral variants, resulting from mutations produced by amino acid
substitutions in the target virus protein that reduce viral sensitivity to DAAs [84]. Resistance-associated variants (RAVs) may be present, despite being usually at low levels even before the beginning of DAAs treatment due to the great genetic variability of HCV [84]. Moreover, genotype 3 virus consistently demonstrates lower SVR rates to DAAs, despite higher SVR rates in other forms of the virus [85].

Since DAAs are widely used for treatment of HCV, the role of resistance-associated variants (RAVs) is becoming clearer.

Natural polymorphisms, before treatment, associated with resistance to NS3/4A, NS5A, and NS5B inhibitors have a considerable prevalence in DAAs naïve patients that is variable and depends on HCV genotype and subtype [86]. These variants may be selected rapidly during treatment with DAAs with the possible consequences of a viral breakthrough and treatment failure [86–88]. For example, the preexisting NS3/4A Q80K, mainly found in patients with HCV genotype 1a (5%–48%), reduces SVR rates in genotype 1a infected patients treated with the protease inhibitor simprevir in combination with PEG-INF/RBV in comparison to those without Q80K [89, 90]. In phase III clinical trials of simprevir and PEG-INF/RBV HCV genotype 1 and genotype 4 infected treatment-naïve patients and prior relapers achieved SVR at week 12 rates of approximately 80% [91–95]. Response rates to therapy were lower in HCV genotype 1 patients with Q80K compared with HCV genotype 1 patients without this polymorphism [7, 9, 11]. The Q80K polymorphism is frequently observed in HCV genotype 1a [96]; meanwhile the occurrence is close to zero in HCV genotype 1b with the only exception of France where 11% of genotype 1b has Q80K [97, 98]. On the basis of these data, the European Medical Agency (EMA) and the Food and Drug Administration (FDA) strongly recommend testing for the presence of Q80K in HCV genotype 1a patients who are candidates to therapy with simprevir and PEG-INF/RBV and discourage the use of this drug when Q80K is detected.

In the IFN-free regimen the presence of Q80K was associated with treatment failure only in a small sample size of patients with genotype 1a and cirrhosis: a phase 3 study (OPTIMIST-2) evaluated the efficacy and safety of 12 weeks of simprevir plus sofosbuvir in HCV genotype 1 infected treatment-naïve or treatment-experienced patients with cirrhosis. Of the 72 patients with chronic HCV genotype 1a, SVR rate was lower for the 34 with Q80K at baseline than for the 38 without Q80K (74% versus 92%) [99]. For this reason, screening for the presence of the Q80K polymorphism should be considered before initiating simprevir in combination with sofosbuvir in cirrhotic patients infected with HCV genotype 1a.

Reduced sensitivity to the first generation protease inhibitors (PIs) (boceprevir and telaprevir) and to the more recent PIs was associated with other NS3/4A mutations, such as those involving the amino acid positions V36, T54, R155, A156, and D168. The list of the major NS3/4A RAVs is reported in Table 3.

The RAVs conferring resistance to NS5A inhibitors more frequently occurred as natural variants in HCV GI infected patients naïve to DAAs [100] and seemed to be more problematic in the setting of retreatment. Y93H is the most frequent baseline NS5A RAV in G1b, followed by L31M/V, while NS5A RAVs are less frequent in G1a [86, 87, 101–103]. L31M confers low-medium level resistance to daclatasvir and ledipasvir, while Y93H/N confers medium-high level resistance to all three approved NS5A inhibitors [100, 104] in G1a but only for ledipasvir in G1b.

Recently, the FDA recommended testing for the presence of virus with NS5A resistance-associated polymorphisms (substitutions at amino acid positions 28, 30, 31, or 93) in genotype 1a, regardless previous treatment history and cirrhosis status, before the combination therapy with grazoprevir and elbasvir to determine dosage regimen and duration (for 12 or 16 weeks and if ribavirin should be added) [101].

It is noteworthy that the persistence of NS5A RAVs has been observed in about 85% of patients with treatment failure over 1-2 years after the start of therapy [100, 105–107]. Therefore, testing polymorphism could be useful prior to retreatment decision because persistent NS5A RAVs could impact the second line therapy success [90]. The list of the major NS5A RAVs is reported in Table 4.

Regarding the NS5B RAVs, no cross resistance is observed across currently approved nucleotide and nonnucleoside polymerase inhibitors. Nucleos(t)ide inhibitors demonstrate activity against different HCV genotypes and have a high resistance barrier [97]. The principal mutation that confers decreased susceptibility to sofosbuvir is S282T and more recently the variants L159F (with/without L320F and C316N) and V321A were detected in patients with failed treatment [108]. M414T and S556G variants were observed in G1a and S556G in G1b patients who did not achieve an SVR after a nonnucleoside analog inhibitor dasabuvir-based regimen [104]. The most relevant NS5B RAVs are reported in Table 5.

Resistance testing at baseline and following treatment failure is not yet indicated, as more data are needed to demonstrate its role in clinical practice, but the unresolved issue is if it may be useful to individualize the best treatment option for each patient in the future. With the exception of Q80K and NS5A RAVs detection in G1a patients before starting simprevir plus PEG-INF/RBV and grazoprevir plus elbasvir, respectively, whether resistance mutation testing should be done in treatment-naïve patients remains controversial.

Some authors highlight the importance of resistance testing in patients who fail multiple DAAs for deciding retreatment and selecting salvage therapy [90, 108, 109]. More recently, Sarrazin encourages also the baseline testing in patients treated with a combination of a first generation NS3/4A protease and NS5A inhibitor with a low barrier of resistance. Instead, in case of treatment with high antiviral activities and high genetic barrier to resistance, the evaluation of additional predictors of response is to be assessed. Moreover, baseline resistance testing may be used to choose the best DAAs regimen in patients with shortened treatment duration or with liver cirrhosis. Sarrazin sustained that in the future it is to evaluate if baseline testing could be cost-effective.
| Position | Variant | Resistant to | Natural prevalence in HCV genotype | Mean fold change in resistance compared to wild-type replicon | References |
|----------|---------|--------------|---------------------------------|-------------------------------------------------|------------|
| V36      | A/C/G   | BOC/TVR/PTV  | n.o. n.o. n.d. n.d. n.d. n.d. | 3 (GT 1a) 2 (GT 1a) 2 (GT 1a) | [87,142,143] |
| V36      | M       | BOC/TVR      | 0.2–0.6% 0.1% n.d. n.d. n.d. n.d. | 3 (GT 1a) 3 (GT 1b) | [87,142–147] |
| F43      | I/L/S/V | SMV/ASV/PTV  | n.o. n.o. n.d. n.d. n.d. n.d. | 2 (GT 1a) 3 (GT 1b) | [86, 144,147,150–153] |
| T54      | A       | BOC/TVR      | 0.1–1.9% n.o. n.d. n.d. n.d. n.d. | 3 (GT 1b) | [87,145–147,153] |
| T54      | S       | BOC/TVR      | 0.4–3.1% 1.2–2.0% n.d. n.d. n.d. n.d. | 1 (GT 1b) | [86,87,144] |
| V55      | A       | BOC/TVR      | 2.8% 0.4% n.d. n.d. n.d. n.d. n.d. | 3 (GT 1b) | [86,87,145–147,153] |
| Y56      | H       | PTV          | n.o. n.o. n.d. n.d. n.d. n.d. n.d. | 6 1 | [86,87,89,144] |
| Q80      | K       | SMV/ASV/PTV  | 4.8–75.0% 0.5–1.2% n.d. n.d. n.d. n.d. | 11 (GT 1a) 3 (GT 1a) 8 (GT 1b) 1 (GT 1b) | [86,144,146, 147,154] |
| Q80      | R       | SMV/ASV      | 0.8% 0.6–0.7% n.d. n.d. n.d. n.d. n.d. | 6 1 | [86,87,89,144] |
| S122     | R       | SMV/ASV      | n.o. n.o. n.d. n.d. n.d. n.d. | 21 | [86,87,144,150] |
| R155     | K/L/G/L/M/T/Q/S | BOC/TVR/SMV/ASV/PTV 0.2–0.9% n.o. n.d. n.d. n.d. n.d. n.d. | 0.2–0.9% n.o. n.d. n.d. n.d. n.d. n.d. | 38 (GT 1b) 58 (GT 1a) 78 (GT 1b) 14 (GT 1a) | [86,87,89,100,142,148,149,143,153,155] |
| A156     | F/N/S/T/V | BOC/TVR/SMV/ASV/PTV | n.o. n.o. n.d. n.d. n.d. n.d. n.d. | 38 (GT 1b) 58 (GT 1a) 78 (GT 1b) 14 (GT 1a) | [86,87,148] |
| V158     | I       | BOC          | n.o. 0.1% n.d. n.d. n.d. n.d. n.d. n.d. | 1 (GT 1b) | [87,143] |
| D168     | E       | SMV/ASV/PTV  | 0.2–0.3% 0.1–1.4% n.d. n.d. n.d. n.d. n.d. | 38 (GT 1b) 58 (GT 1a) 78 (GT 1b) 14 (GT 1a) | [86,87,148] |
| D168     | G/H/V/TY | SMV/ASV/PTV | n.o. n.o. n.d. n.d. n.d. n.d. n.d. n.d. | 38 (GT 1b) 58 (GT 1a) 78 (GT 1b) 14 (GT 1a) | [86,87,148] |
| V170     | A       | BOC/TVR      | n.a. 0.1% n.d. n.d. n.d. n.d. n.d. n.d. | 38 (GT 1b) 58 (GT 1a) 78 (GT 1b) 14 (GT 1a) | [87,142] |
| M175     | L       | BOC          | n.a. 0.8–1.1% n.d. n.d. n.d. n.d. n.d. n.d. | 38 (GT 1b) 58 (GT 1a) 78 (GT 1b) 14 (GT 1a) | [87,143] |

BOC: boceprevir; TVR: telaprevir; SMV: simeprevir; ASV: asunaprevir; PTV: paritaprevir.

n.a.: not applicable because of different natural amino acid sequence in the respective HCV geno-/subtype (V170 and M175 are the dominant amino acids in GT1b).
n.o.: not observed.
n.d.: no data available.

GT: genotype.
Table 4: Natural prevalence of NS5A inhibitor resistance-associated variants (RAVs) detected by population sequencing and mean fold change in resistance associated with RAVs.

| Position | Variant | Resistant to | Natural prevalence in HCV genotype | Mean fold change in resistance compared to wild-type replicon | References |
|----------|---------|--------------|-------------------------------------|---------------------------------------------------------------|------------|
|          |         |              |                                     | Daclatasvir | Ledipasvir | Ombitasvir |                             |                        |
| K24      | G/N     | LDV          | n.o.                                | n.a.        | n.d.       | n.d.       | n.d.                        | [156]                  |
| K24      | R       | LDV          | <1-1.5%                             | n.a.        | n.d.       | n.d.       | n.d.                        | [155, 157]             |
| M28      | A       | DCV/LDV      | 0.5%                                | n.d.        | n.d.       | n.d.       | n.d.                        | [156]                  |
| M28      | G       | LDV          | n.o.                                | n.d.        | n.d.       | n.d.       | n.d.                        | [86, 156]              |
| M28      | T       | DCV/LDV/OMV  | 0.4-1.8%                            | n.d.        | n.o.       | 82.0% (M24L) | n.d.                        | 205 61 8,965          |
| M28      | V       | OMV          | 3.5%                                | n.d.        | n.d.       | n.d.       | n.d.                        | 58 (GT 1a)             |
| F28      | S       | DCV          | n.a.                                | n.o.        | n.d.       | n.d.       | n.d.                        | [164]                  |
| L28      | F/T     | DCV/OMV      | n.o.                                | n.o.        | 8.0%       | n.d.       | n.d.                        | [86, 87, 156]          |
| Q30      | H/R/E/L/T| DCV/LDV/OMV | 0.3-1.3%                            | n.a.        | n.d.       | 90.4-100% | 50.0-100%                   | n.d.                    |
| R30      | H       | DCV          | n.a.                                | 0.4%        | n.d.       | n.o.       | n.d.                        | [166]                  |
| R30      | S       | DCV          | n.a.                                | n.d.        | n.d.       | 10%        | n.d.                        | [166]                  |
| R30      | G/H     | DCV          | n.a.                                | n.d.        | n.d.       | n.o.       | n.d.                        | [166]                  |
| A30      | K       | DCV          | n.a.                                | n.d.        | 2.3-6.3%   | n.d.       | n.d.                        | [167]                  |
| L31      | M       | DCV/LDV      | 0.9-1.8%                            | 2.1-6.3%    | 74.0-85.0% | 1%         | 92.5-100%                   | n.d.                    |
| L31      | I/F/V   | DCV/LDV/OMV  | n.o.                                | 0.7-1%      | n.d.       | n.o.       | n.d.                        | 15 (L3IV)              |
| P32      | L       | DCV/LDV      | n.o.                                | <0.5%       | n.d.       | n.o.       | n.d.                        | [156]                  |
| S38      | F       | LDV          | n.o.                                | n.o.        | n.d.       | n.d.       | n.d.                        | [156]                  |
| H58      | D       | DCV/LDV/OMV  | <1%                                 | n.a.        | n.d.       | n.d.       | n.d.                        | 1,127 243              |
| P58      | D       | LDV          | n.o.                                | n.o.        | n.d.       | n.d.       | n.d.                        | [156]                  |
| A92      | K       | LDV          | n.o.                                | n.o.        | n.d.       | n.d.       | n.d.                        | [156]                  |
| A92      | T       | LDV          | n.o.                                | 2.8%        | n.d.       | n.d.       | n.d.                        | [156]                  |
| C92      | R       | DCV          | n.o.                                | n.o.        | n.o.       | n.d.       | n.d.                        | [156]                  |
| Y93      | C/F/N   | DCV/LDV/OMV  | n.o.~0.6%                           | n.o.~0.7%   | n.d.       | n.o.       | n.d.                        | [156]                  |
| Y93      | H       | DCV/LDV/OMV  | <1.5%                               | 3.8-14.1%   | n.o.       | 1.3-8.3%  | 5-13%                      | 12 77 164-167,169-175  |
| Y93      | S       | LDV          | <0.5%                               | <0.5%       | n.d.       | n.d.       | n.d.                        | [156]                  |

DCV: daclatasvir; LDV: ledipasvir; OBV: ombitasvir.

n:a: not applicable because of different natural amino acid sequence in the respective HCV geno-/subtype (K24, M28, Q30, and H58 are the dominant amino acids in GT1a; F28 is the dominant amino acid in subtype 2a and L28 in subtype 2b; A30 is the dominant amino acid in GT3).

n.o.: not observed.

n.d.: no data available.

GT: genotype.
Table 5: Natural prevalence of NS5B nucleotide and nonnucleoside inhibitor resistance-associated variants (RAVs) detected by population sequencing and mean fold change in resistance associated with RAVs.

| Position | Variant | Resistant to | Natural prevalence in HCV genotype | Mean fold change in resistance compared to wild-type replicon | References |
|----------|---------|--------------|-----------------------------------|------------------------------------------------------------|------------|
|          |         |              | la | lb | 2 | 3 | 4 | 5 | 6 | Sofosbuvir | Dasabuvir |
| S28      | 2T      | SOF          | n.o. | n.o. | n.o. | n.o. | n.d. | n.d. | n.d. | 16 | [87, 142, 176–180] |
| M289     | I/L     | SOF          | n.o. | 1.8% | 3.5% | n.d. | n.d. | n.d. | n.d. | 1472 (GT 1a) | [86, 87, 100, 165, 175] |
|          |         | DSV          | 0.2–1.2% | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | 1569 (GT 1b) | [86, 87, 100, 165, 181] |
| C316     | Y       | DSV          | 10.9–35.6% | n.d. | n.d. | 7.9% | n.d. | n.d. | n.d. | [176] |
| C316     | N       | DSV/SOF      | 0.2–1.2% | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [86, 163, 181] |
| C316     | H       | DSV/SOF      | 1.9–2.1% | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | [86, 165] |
| L320     | F       | SOF          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [165] |
| S368     | T       | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [86, 142] |
| N411     | S       | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [86, 142] |
| M414     | T       | DSV          | 0.5% | 0.4% | n.d. | n.d. | n.d. | n.d. | n.d. | 32 (GT 1b) | [87, 100, 175, 182] |
| M414     | I       | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [87, 142] |
| E446     | K/Q     | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [165] |
| Y448     | C       | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [86, 142] |
| Y448     | H       | DSV          | 0.2% | 1.3% | n.d. | n.d. | n.d. | n.d. | n.d. | 975 (GT 1a) | [87, 144] |
| A535     | I/T/V   | DSV          | 6% | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [165] |
| G534     | S/D     | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [86, 142] |
| S556     | G       | DSV          | 0.6–3.1% | 7.0–16% | 100% | 100% | 97% | n.d. | n.d. | 30 (GT 1a) | [86, 163, 181, 182] |
| S556     | N/R     | DSV          | 0.6–1.2% | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | 11 (GT 1b) | [86, 163, 181, 182] |
| G558     | R       | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [86, 182] |
| D559     | G       | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [165] |
| Y561     | H       | DSV          | n.o. | n.o. | n.d. | n.d. | n.d. | n.d. | n.d. | [165] |

SOF: sofosbuvir; DSV: dasabuvir.
n.o.: not observed.
n.d.: no data available.
GT: genotype.
in order to prevent nonresponse to very expensive treatment, particularly in regions with economical restriction [100].

4. How Close Is an Effective Preventive HCV Vaccine?

The development of an effective HCV vaccine is hampered by several factors. First, HCV is characterized by an extraordinary genetic variability resulting from the lack of proofreading activity of the NS5B RNA-dependent polymerase [110]. This determines an impressive error rate per replication cycle that, in combination with the short viral half-life and the rapid turnover, leads to the generation of multiple distinct but closely related HCV variants, known as "quasispecies," in one infected subject [111, 112]. Mutated viruses have the ability to persist in infected people by escaping immune control of cytotoxic T lymphocytes (CTL) and antibodies against different regions of the viral envelope [113, 114].

In addition to evading antibody and CTL recognition by passively mutating its genome in response to immune pressure, HCV exploits several further strategies to escape adaptive immune response and achieve a high rate of chronic infection. In fact, HCV, through a yet-unknown mechanism, fails to properly initiate the CD4+ T cell response at the beginning of infection and determines a rapid immune exhaustion and depletion of CD8+ T cells [115–117]. Moreover, HCV is able to hide from humoral immunity and pass from cell to cell without being exposed to the circulating antibodies by (i) binding low density lipoproteins, thus limiting the production of neutralizing antibodies during acute infection, (ii) decreasing viral immunogenicity through the presence of three glycans at the CD81 binding site of E2 glycoprotein, (iii) infecting surrounding cells through cell-to-cell contact mediated by CD81 and Claudin-1, and (iv) inducing interfering antibodies by constant mutation [118].

The weaker and ineffective adaptive immune response to HCV mainly contributes to the infection progressing into a chronic state. On the other hand, these immune evasion mechanisms have relevant implications in the development of the HCV vaccine. In fact, an effective vaccine should be able to induce strong neutralizing antibodies as well as powerful cellular immune responses during the very first stages of the HCV infection, before the virus has the chance to activate its many immune escape mechanisms [119].

A further barrier that has challenged the research on HCV vaccine is the lack of convenient experimental model systems for the study of HCV pathogenesis and vaccine design. To date, the only suitable infectious animal model is the chimpanzee. However, some ethical issues, the high cost of acquiring and maintaining the chimpanzees, and their limited supply restricted the use of these animals and the statistical power of studies [8, 120]. Furthermore, immune response of chimpanzees to HCV greatly differs from humans. Therefore, immunological results obtained with this model should be prudently interpreted [121, 122].

Several strategies have been adopted to develop an effective preventive HCV vaccine. They ranged from the traditional strategy of producing recombinant envelope proteins combining them with adjuvant substances to complex manufacturing of viral vectors directing the expression of multiple viral antigens. All strategies have been targeted to enhance the T cell response and, in particular, to determine a long-lasting cellular immune responses involving helper CD4+ and CD8+ T cells rather than only improving humoral responses.

Despite two decades of research efforts, few HCV candidate vaccines have reached the clinical trials phase and the evidences on both the efficacy and safety of these vaccines in humans remain limited (Table 6).

The first prophylactic HCV vaccine tested in human beings was a C-terminally shortened recombinant E1 protein adjuvant with aluminum hydroxide, called T2S-918/InnoVac-C, demonstrating good tolerability and good antibody response against E1. Moreover, a robust specific cellular immune response towards E1 was stimulated in all vaccinees [123]. However, the studies on this candidate vaccine were stopped in 2007.

Further HCV prophylactic vaccines based on recombinant proteins combined with adjuvant substances have been developed and evaluated in clinical trials.

A recombinant E1/E2 heterodimer vaccine (derived from HCV 1a) adjuvant with MF59C was tested in phase I clinical trial involving 60 healthy subjects. Vaccine demonstrated inducing neutralizing antibodies and T cell responses to E1/E2 in all subjects. Although the vaccine was safe and well-tolerated, its usage was prevented by manufacturing difficulties [124].

Another approach, based on recombinant protein, consisted of combining recombinant HCV core protein with an adjuvant substance, called ISCOMATRIX™. In a phase I clinical trial, conducted on 30 healthy volunteers, all subjects except one demonstrated antibodies against HCV core protein, without indication of a dose response. However, T cell responses were detected in only two subjects who received the highest dose of vaccine. The candidate vaccine was generally well-tolerated [125].

Also the development strategies based on HCV peptides vaccine that were able to induce HCV specific T cell responses by presenting vaccine peptide to the T cell receptor via HLA molecules have obtained some encouraging findings.

In particular, a peptide vaccine, known as IC41 and consisting of five synthetic peptides derived from conserved regions of core, NS3 and NS4 proteins of HCV genotypes 1 and 2 with a poly-L-arginine adjuvant, was evaluated in 128 healthy volunteers in a phase I clinical trial where it resulted in being safe and well-tolerated [126]. On the other hand, IC41 elicited few interferon-producing cells and dose-dependent T cell immune responses, even though a correlation between higher responder rates with dose and number of vaccinations was demonstrated [127]. In a successive randomized clinical trial, 54 healthy subjects received either subcutaneous or intradermal IC41 vaccine weekly (16 injections) or every other week (8 injections). One group additionally received imiquimod, an activator of the toll-like receptor (TLR) 7. Results showed that IC41 induced significant immunological responses in all groups with responder rates of up to 100%, even though imiquimod was not able to increase immunogenicity but was associated with a lower immune
Table 6: Preventive hepatitis C virus vaccine tested in clinical trials.

| Type of vaccine      | Viral component                                           | Adjuvant       | Phase of clinical trial | Study population         | Year  | Reference |
|----------------------|-----------------------------------------------------------|----------------|-------------------------|--------------------------|-------|-----------|
| Recombinant protein  | Recombinant E1 protein                                    | Aluminum hydroxide | I                       | 20 healthy subjects      | 2004  | [123]    |
|                      | Recombinant E1 and E2 proteins                            | MF59           | I                       | 60 healthy subjects      | 2010  | [124]    |
|                      | Recombinant core protein                                  | ISCOMATRIX     | I                       | 60 healthy subjects      | 2009  | [125]    |
| Peptide              | Five synthetic peptides derived from conserved regions of  | Poly-L-arginine | I                       | 128 healthy subjects     | 2006  | [126]    |
|                      | core, NS3, and NS4 proteins of HCV genotypes 1 and 2 (IC41) |                |                         |                          |       |           |
|                      | Five synthetic peptides derived from conserved regions of  | Poly-L-arginine | I                       | 54 healthy subjects      | 2010  | [127]    |
|                      | core, NS3, and NS4 proteins of HCV genotypes 1 and 2 (IC41) |                |                         |                          |       |           |
| Virally vectored     | Human adenovirus rare serotype 6 (HADV6) and chimpanzee   | —              | I                       | 30 healthy subjects      | 2012  | [128]    |
|                      | Ad 3 (ChAd3) expressing the HCV nonstructural proteins    |                |                         |                          |       |           |
response. Intradermal injections caused more pronounced reactions, especially erythema and edema, but immunization with IC41 resulted generally in being safe and well-tolerated [127].

More innovative strategies to develop an effective HCV preventive vaccine include the manufacturing of DNA vaccine and viral vectors expressing HCV genes. DNA vaccines showed the capability of inducing cytotoxic lymphocyte responses in animal models; however, the induced immunity is often brief, weak, and unlikely to be effective in infection prevention. Viral vectors able to express foreign antigens represent an effective tool to induce a broader CD4+ and CD8+ T cell responses, compared to peptide vaccines.

Two preventive vaccines based on human adenovirus rare serotype 6 (HADV6) and chimpanzee Ad 3 (ChAd3) expressing the HCV nonstructural proteins were tested in a phase I clinical trial conducted on 36 healthy volunteers. The study demonstrated that both vaccines induced specific T cell responses against multiple HCV proteins and T cell were capable of recognizing heterologous HCV strains (genotypes 1a and 3a). These data suggested that an adenoviral vector strategy may induce sustained T cell responses of a magnitude and quality associated with protective immunity, thus encouraging studies of novel prophylactic vaccines for HCV [128].

On the basis of some promising data obtained in phase I clinical trials, different types of prophylactic HCV vaccine are approaching phase II and phase III clinical trials [129]. In the next future, research efforts should be focused on improving the selection of the viral component and the proper administration regimens as well as on the safety and the tolerability of candidate preventive HCV vaccines.

5. Further Therapeutic Options

Research efforts for the development of alternative therapeutic options have been made contextually to the development of DAAs and the research on preventive vaccines. To date, several approaches have been adopted in the development and production of HCV therapeutic vaccines including peptide vaccines, recombinant protein vaccines, DNA vaccines with different carriers, and virally vectored vaccines.

Some studies were conducted among chronic hepatitis C patients, obtaining promising results in terms of T cell proliferation and IFN-γ responses and SVR rates within patients treated with interferon [130, 131].

Clinical trials, conducted by administering candidate HCV therapeutic vaccines in HCV chronic infected patients, have demonstrated HCV specific immune responses and transiently reduction of viral RNA, but the vaccines were not able to completely clear HCV infection or consistently reduce viral titers [130, 132, 133].

Some authors discussed the possibility to improve the efficacy of these vaccines by prior treatment with DAAs to first suppress HCV viremia [9], but the promising results obtained with the new generation of DAAs and their combination in curing HCV patients may overcome the use of therapeutic vaccination as an effective strategy for HCV treatment.

A further therapeutic option to cure HCV is represented by neutralizing monoclonal antibodies (mAbs) directed against HCV envelope glycoproteins E1 and E2, which are involved in the HCV entry into host cells or against phospholipids expressed on infected host cells [134, 135]. With respect to mAbs directed against viral antigens, due to the low immunogenicity of E1 glycoprotein, the research mainly focused on mAbs targeted conserved regions of E2 glycoprotein. To date, two mAbs directed against this target have been investigated in phase I and phase II clinical trials in the prevention of HCV reinfection during and after liver transplantation.

Two studies involved anti-HCV/2 human mAb HCV-AB68 demonstrating only a modest and short-lasting reduction in viremia [136, 137]. More recently, MBL-HCV1 showed good tolerability, reduced viral load, and delayed median time to viral rebound compared to placebo treatment in a phase II clinical trial involving II patients infected with HCV genotype 1a [138].

As regards mAbs against host receptors, a phase II unpublished clinical trial involving bavituximab was conducted to study the safety profile and early virological response in HCV genotype 1 infected patients treated with this mAb in combination with ribavirin in comparison with patients treated with PEG-INF/RBV [135].

In recent years, novel mAbs with immunomodulatory effects have been explored. Among these, mAbs that target programmed death 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and CD3 receptors were established clinical trial involving bavituximab was conducted to study the safety profile and early virological response in HCV genotype 1 infected patients treated with this mAb in combination with ribavirin in comparison with patients treated with PEG-INF/RBV [135].

In recent years, novel mAbs with immunomodulatory effects have been explored. Among these, mAbs that target programmed death 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and CD3 receptors were studied in phase II clinical trials with encouraging results in terms of safety, tolerability, and viral response [139–141].

The most likely future for clinical use of mAbs is represented by regimens for HCV treatment consisting of mAb cocktails or combination of mAbs with other available drugs with the main goal of avoiding viral escape and the development of resistance.

6. Conclusions

Substantial advances have been made in HCV research and treatment in recent years. Although highly effective anti-HCV drugs are now available, these treatments remain poorly accessible because of their high costs; moreover, their efficacy is challenged by the high frequency of resistance-associated mutations. A further major obstacle for the control of the disease is represented by the lack of availability of an effective screening strategy to identify all people in need of treatment. Therefore, even though new drugs may contribute to impacting HCV spread worldwide, substantially modifying the natural history of the disease, eradication will be reached only through the development of an effective prophylactic vaccine. Future research directions should bridge this gap and progress in the comprehension of biological and immunological mechanisms of the disease and advances in molecular vaccinology, together with a strong financial, political, and societal support, will enable reaching this fundamental success in the coming years.
Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

All the authors contributed equally to this paper.

References

[1] B. R. Edlin, “Perspective: test and treat this silent killer,” Nature, vol. 474, no. 7350, pp. S18–S19, 2011.

[2] Center for Disease Control and Prevention (CDC), “Surveillance for Viral Hepatitis—United States,” 2013, http://www.cdc.gov/hepatitis/statistics/2013surveillance/commentary.htm#hepatitisC.

[3] E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi, “Global epidemiology and genotype distribution of the hepatitis C virus infection,” Journal of Hepatology, vol. 61, no. 1, pp. S45–S57, 2014.

[4] I. F. Kretzer, A. do Livramento, J. da Cunha et al., “Hepatitis C worldwide and in Brazil: silent epidemic—data on disease including incidence, transmission, prevention, and treatment,” The Scientific World Journal, vol. 2014, Article ID 827849, 10 pages, 2014.

[5] J. Grebely, K. Page, R. Sacks-Davis et al., “The effects of female sex, viral genotype, and IL28B genotype on spontaneous clear-ance of acute hepatitis C virus infection,” Hepatology, vol. 59, no. 1, pp. 109–120, 2014.

[6] H.-H. Thein, Q. Yi, G. J. Dore, and M. D. Krahn, “Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression,” Hepatology, vol. 48, no. 2, pp. 418–431, 2008.

[7] R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, no. 9859, pp. 2095–2128, 2012.

[8] T. J. Liang, “Current progress in development of hepatitis C virus vaccines,” Nature Medicine, vol. 19, no. 7, pp. 869–878, 2013.

[9] L. Man John Law, A. Landi, W. C. Magee, D. Lorne Tyrrell, and M. Houghton, “Progress towards a hepatitis C virus vaccine,” Emerging Microbes and Infections, vol. 2, article e79, 2013.

[10] M. L. Shiffman, “Universal screening for chronic hepatitis C virus,” Liver International, vol. 36, no. SI, pp. 62–66, 2016.

[11] J. Bottero, C. Brouard, F. Roudot-Thoraval et al., “2014 French guidelines for hepatitis B and C screening. A combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV” Liver International, vol. 36, no. 10, pp. 1442–1449, 2016.

[12] P. Easterbrook, C. Johnson, C. Figueroa, and R. Baggaley, “HIV and hepatitis testing: global progress, challenges, and future directions,” AIDS Reviews, vol. 18, no. 1, pp. 3–14, 2016.

[13] M. M. Denniston, R. M. Klevens, G. M. McQuillan, and R. B. Jiles, “Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008,” Hepatology, vol. 55, no. 6, pp. 1652–1661, 2012.

[14] World Health Organization, “Hepatitis C,” Fact Sheet 164, World Health Organization, Geneva, Switzerland, 2015, http://www.who.int/mediacentre/factsheets/fs164/en/.

[15] World Health Organization, “Global policy report on the prevention and control of viral hepatitis in WHO Member States,” 2013, http://apps.who.int/iris/bitstream/10665/85397/1/9789241564632_eng.pdf.

[16] World Health Organization, “Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection,” http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1.

[17] S. Kamili, J. Drobeniuc, A. C. Araujo, and T. M. Hayden, “Laboratory diagnostics for hepatitis C virus infection,” Clinical Infectious Diseases, vol. 55, supplement 1, pp. S43–S48, 2012.

[18] L. M. Villar, H. M. Cruz, C. S. Barbosa Bezerra Jr., M. M. Portilio, and P. Scaloni Lde, “Update on hepatitis B and C virus diagnosis,” World Journal of Virology, vol. 4, no. 4, pp. 323–342, 2015.

[19] H. C. Li and S. Y. Lo, “Hepatitis C virus: virology, diagnosis and treatment,” World Journal of Hepatology, vol. 7, no. 10, pp. 1377–1389, 2015.

[20] C. V. Uliana, C. S. Riccardi, and H. Yamanaka, “Diagnostic tests for hepatitis C: recent trends in electrochemical immunosensor and genosensor analysis,” World Journal of Gastroenterology, vol. 20, no. 42, pp. 15476–15491, 2014.

[21] S. Chevaliez and J.-M. Pawlotsky, “Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease,” International Journal of Medical Sciences, vol. 3, no. 2, pp. 35–40, 2006.

[22] F. Alborino, A. Burighel, F.-W. Tiller et al., “Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity,” Medical Microbiology and Immunology, vol. 200, no. 2, pp. 77–83, 2011.

[23] C. Colin, D. Lanoir, S. Touzet, L. Meyaud-Kraemer, F. Bailly, and C. Trepo, “Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature,” Journal of Viral Hepatitis, vol. 8, no. 2, pp. 87–95, 2001.

[24] J. M. Barrera, B. Francis, G. ERCilla et al., “Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA,” Vox Sang, no. 1, pp. 15–18, 1995.

[25] C. L. Mack, R. F. Gonzalez-Peralta, N. Gupta et al., “NASPGHAN Practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents,” Journal of Pediatric Gastroenterology and Nutrition, vol. 54, no. 6, pp. 838–855, 2012.

[26] M. C. Medic, G. Furlini, A. Rodella et al., “Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoas say,” Journal of Clinical Virology, vol. 31, no. 4, pp. 264–269, 2011.

[27] F. V. Cresswell, M. Fisher, D. J. Hughes, S. G. Shaw, G. Homer, and M. O. Hassan-Ibrahim, “Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection,” Clinical Infectious Diseases, vol. 60, no. 2, pp. 263–266, 2015.

[28] B. D. Smith, R. L. Morgan, A. Beckett, Y. Falck-Ytter, D. Holtzman, and J. W. Ward, “Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention,” Annals of Internal Medicine, vol. 157, no. 11, pp. 817–822, 2012.

[29] Haute Autorité de Santé (HAS), Use of Rapid Point-of-Care First-Line Screening Tests in Hepatitis C Screening Strategy, Haute Autorité de Santé (HAS), Saint Denis, France, 2014.
[30] S. Shivkumar, R. Peeling, Y. Jafari, L. Joseph, and N. Pant Pai, "Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis," *Annals of Internal Medicine*, vol. 157, no. 8, pp. 558–566, 2012.

[31] L. D. P. Scallion, H. M. Cruz, V. S. de Paula et al., "Performance of rapid hepatitis C virus antibody assays among high- and low-risk populations," *Journal of Clinical Virology*, vol. 60, no. 3, pp. 200–205, 2014.

[32] M. S. Khuroo, N. S. Khuroo, and M. S. Khuroo, "Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis," *PLoS ONE*, vol. 10, no. 3, Article ID e0121450, 2015.

[33] National Institute for Health and Clinical Excellence (NICE), Hepatitis B and C: Ways to Promote and Offer Testing to People at Increased Risk of Infection, NICE, London, UK, 2012, http://www.nice.org.uk/nicemedia/live/14003/61863/61863.pdf.

[34] Centers for Disease Control and Prevention (CDC), "Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965," *Morbidity and Mortality Weekly Report (MMWR)*, vol. 61, no. RR04, pp. 1–32, 2012, http://www.cdc.gov/mmwr/pdf/rr/rr6104.pdf.

[35] AASLD/IDSA HCV Guidance Panel, "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus," *Hepatology*, vol. 62, no. 3, pp. 932–954, 2015.

[36] B. D. Smith, R. L. Morgan, G. A. Beckett et al., "Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965*, MMWR Recommendations and Reports, vol. 61, no. 4, pp. 1–32, 2012.

[37] V. A. Moyer, "Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. Preventive Services Task Force recommendation statement," *Annals of Internal Medicine*, vol. 159, no. 3, pp. 210–218, 2013.

[38] T. M. Shehab, S. S. Sonnad, and A. S. F. Lok, "Management of hepatitis C patients by primary care physicians in the USA: results of a national survey," *Journal of Viral Hepatitis*, vol. 8, no. 5, pp. 377–383, 2001.

[39] T. M. Shehab, M. Orrego, R. Chunduri, and A. S. F. Lok, "Identification and management of hepatitis C patients in primary care clinics," *The American Journal of Gastroenterology*, vol. 98, no. 3, pp. 639–644, 2003.

[40] R. Mahajan, S. J. Liu, R. M. Klevens, and S. D. Holmberg, "Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004–2010," *American Journal of Public Health*, vol. 103, no. 8, pp. 1445–1449, 2013.

[41] L. Hsu, C. L. Bowlus, S. L. Stewart et al., "Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial," *Digestive Diseases and Sciences*, vol. 58, no. 3, pp. 807–814, 2013.

[42] J. W. Galbraith, R. A. Franco, J. P. Donnelly et al., "Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department," *Hepatology*, vol. 61, no. 3, pp. 776–782, 2015.

[43] B. J. Turner, B. S. Taylor, J. T. Hanson et al., "Implementing hospital-based baby boomer hepatitis C virus screening and linkage to care: strategies, results, and costs," *Journal of Hospital Medicine*, vol. 10, no. 8, pp. 510–516, 2015.

[44] D. M. Sears, D. C. Cohen, K. Ackerman, J. E. Ma, and J. Song, "Birth cohort screening for chronic hepatitis during colonoscopy appointments," *American Journal of Gastroenterology*, vol. 108, no. 6, pp. 981–989, 2013.

[45] R. P. Myers, P. Crotty, S. Town et al., "Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study," *CMAJ Open*, vol. 3, no. 1, pp. E62–E67, 2015.

[46] N. J. Shire and K. E. Sherman, "Epidemiology of hepatitis C virus: a battle on new frontiers," *Gastroenterology Clinics of North America*, vol. 44, no. 4, pp. 699–716, 2015.

[47] J. Nakamura, K. Terajima, Y. Aoyagi, and K. Akazawa, "Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups," *The Tohoku Journal of Experimental Medicine*, vol. 215, no. 1, pp. 33–42, 2008.

[48] S. J. M. Hahné, I. K. Veldhuijzen, L. Wiessing, T.-A. Lim, M. Salminen, and M. V. D. Laar, "Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening," *BMC Infectious Diseases*, vol. 13, no. 1, article 181, 2013.

[49] A. Kautz, L. Chavdarova, and M. Walker, "Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe," *BMC Infectious Diseases*, vol. 14, supplement 6, article S3, 2014.

[50] G. Dultz and S. Zeuzem, "Hepatitis C virus: a European perspective," *Gastroenterology Clinics of North America*, vol. 44, no. 4, pp. 807–824, 2015.

[51] S. Lubega, U. Agbim, M. Surjadi, M. Mahoney, and M. Khalili, "Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response," *Liver International*, vol. 33, no. 7, pp. 999–1007, 2013.

[52] G. Wagner, K. C. Osilla, J. Garnett et al., "Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients," *Journal of the International Association of Physicians in AIDS Care*, vol. 11, no. 4, pp. 245–251, 2012.

[53] N. Islam, Y. N. Flores, P. Ramirez, R. Bastani, and J. Salmerón, "Hepatitis B and liver disease knowledge and preventive practices among health workers in Mexico: a cross-sectional study," *International Journal of Public Health*, vol. 59, no. 2, pp. 381–394, 2014.

[54] J. Grebely, J. Bryant, P. Hull et al., "Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia," *Journal of Viral Hepatitis*, vol. 18, no. 4, pp. e104–e116, 2011.

[55] J. A. Aberg, J. E. Gallant, K. G. Ghanem, P. Emmanuel, B. S. Zingman, and M. A. Horberg, "Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America," *Clinical Infectious Diseases*, vol. 58, no. 1, pp. 1–10, 2014.

[56] B. P. Linas, A. Y. Wong, B. R. Schackman, A. Y. Kim, and K. A. Freedberg, "Cost-effective screening for acute hepatitis C virus infection in hiv-infected men who have sex with men," *Clinical Infectious Diseases*, vol. 55, no. 2, pp. 279–290, 2012.

[57] G. Wandelzer, T. Gsponer, A. Bregenzer et al., "Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic," *Clinical Infectious Diseases*, vol. 55, no. 10, pp. 1408–1416, 2012.

[58] M. D. Witt, E. C. Seaberg, A. Darilay et al., "Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984–2011," *Clinical Infectious Diseases*, vol. 57, no. 1, pp. 77–84, 2013.

[59] M. J. Bravo, F. Vallejo, G. Barrio et al., "HCV seroconversion among never-injecting heroin users at baseline: no predictors
identified other than starting injection,” *International Journal of Drug Policy*, vol. 23, no. 5, pp. 415–419, 2012.

60. I. T. Williams, B. P. Bell, W. Kuhnert, and M. J. Alter, “Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006,” *Archives of Internal Medicine*, vol. 171, no. 3, pp. 242–248, 2011.

61. J. P. Meyer, Y. Moghimi, R. Marcus, J. K. Lim, A. H. Litwin, and F. L. Altice, “Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum,” *International Journal of Drug Policy*, vol. 26, no. 10, pp. 922–935, 2015.

62. A. C. Moorman, S. C. Gordon, L. B. Rupp et al., “Baseline characteristics and mortality among people in care for chronic viral hepatitidis: the chronic hepatitis cohort study,” *Clinical Infectious Diseases*, vol. 56, no. 1, pp. 40–50, 2013.

63. Y. Liu, R. H. Lawrence, Y. Falck-Ytter, B. Watts, and A. A. Hirsch, “Evaluating a hepatitis c quality gap: missed opportunities for HCV-related cares,” *American Journal of Managed Care*, vol. 20, no. 7, pp. e257–e264, 2014.

64. O. S. Khokhar and J. H. Lewis, “Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?” *Digestive Diseases and Sciences*, vol. 52, no. 5, pp. 1168–1176, 2007.

65. S. Arora, K. Thornton, G. Murata et al., “Outcomes of treatment for hepatitis C virus infection by primary care providers,” *New England Journal of Medicine*, vol. 364, no. 23, pp. 2199–2207, 2011.

66. B. T. Clark, G. Garcia-Tsao, and L. Fraenkel, “Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection,” *Patient Preference and Adherence*, vol. 6, pp. 285–295, 2012.

67. L. L. Seifert, R. B. Perumpail, and A. Ahmed, “Update on hepatitis with chronic hepatitis C virusinfection,” *Clinical Infectious Diseases*, vol. 56, no. 1, pp. 40–50, 2013.

68. L. Highleyman, “Hepatitis C cascade studies show gaps in testing and treatment,” http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/4693-hepatitis-c-cascade-studies-show-gaps-in-testing-and-treatment.

69. S. D. Holmberg, P. R. Spradling, A. C. Moorman, and M. M. Denniston, “Hepatitis C in the United States,” *The New England Journal of Medicine*, vol. 368, no. 20, pp. 1859–1861, 2013.

70. M. Hellard, R. Sacks–Davis, and J. Gold, “Hepatitis C treatment for injection drug users: a review of the available evidence,” *Clinical Infectious Diseases*, vol. 49, no. 4, pp. 561–573, 2009.

71. J. A. Morrill, M. Shrestha, and R. W. Grant, “Barriers to the treatment of hepatitis C patient, provider, and system factors,” *Journal of General Internal Medicine*, vol. 20, no. 8, pp. 754–758, 2005.

72. B. Reilley, J. Leston, J. T. Redd, and R. Geiger, “Lack of access to treatment as a barrier to HCV screening: a facility-based assessment in the Indian health service,” *Journal of Public Health Management and Practice*, vol. 20, no. 4, pp. 420–423, 2014.

73. C. E. McGowan, A. Monis, B. R. Bacon et al., “A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care,” *Hepatology*, vol. 57, no. 4, pp. 1325–1332, 2013.

74. M. M. Islam, L. Topp, K. M. Conigrave et al., “Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre,” *Journal of Substance Abuse Treatment*, vol. 43, no. 4, pp. 440–445, 2012.
N. Coppola, C. Minichini, M. Starace, C. Sagnelli, and E. Sagnelli, “Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals,” Journal of Medical Virology, vol. 88, no. 10, pp. 1659–1671, 2016.

P. Krishnan, R. Tripathi, G. Schnell et al., “Long-term follow-up of treatment-emergent resistance-associated variants in NS5a, NS5A and NS5B with paritaprevir/rit-, ombitasvir- and dasabuvir-based regimens,” Journal of Hepatology, vol. 62, supplement 2, p. S220, 2015.

F. Mcphee, D. Hernandez, F. Yu et al., “Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir,” Hepatology, vol. 58, no. 3, pp. 902–911, 2013.

H. Dvory-Sobol, D. Wyles, W. Ouyang et al., “Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir,” Journal of Hepatology, vol. 62, supplement 2, p. S221, 2015.

V. Cento, S. Chevaliez, and C. E. Perno, “Resistance to direct-acting antiviral agents: clinical utility and significance,” Current Opinion in HIV and AIDS, vol. 10, no. 5, pp. 381–389, 2015.

M. Buti, M. Riveiro-Barciela, and R. Esteban, “Management of direct-acting antiviral agent failures,” Journal of Hepatology, vol. 63, no. 6, pp. 1511–1522, 2015.

S. Duffy, L. A. Shackelton, and E. C. Holmes, “Rates of evolutionary change in viruses: patterns and determinants,” Nature Reviews Genetics, vol. 9, no. 4, pp. 267–276, 2008.

J. Bukh, R. H. Miller, and R. H. Purcell, “Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes,” Seminars in Liver Disease, vol. 15, no. 1, pp. 41–63, 1995.

P. Simmonds, “Viral heterogeneity of the hepatitis C virus,” Journal of Hepatology, vol. 31, supplement 1, pp. 54–60, 1999.

D. G. Bowen and C. M. Walker, “Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man,” Journal of Experimental Medicine, vol. 201, no. 11, pp. 1709–1714, 2005.

T. von Hahn, J. C. Yoon, H. Alter et al., “Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo,” Gastroenterology, vol. 132, no. 2, pp. 667–678, 2007.

B. Rehermann, “Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses,” Seminars in Liver Disease, vol. 27, no. 2, pp. 152–160, 2007.

A. Penna, M. Pilli, A. Zerbini et al., “Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection,” Hepatology, vol. 45, no. 3, pp. 588–601, 2007.

J. R. Larrubia, M. U. Lokhande, S. García-Garzón et al., “Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation,” Journal of Viral Hepatitis, vol. 20, no. 2, pp. 85–94, 2013.

J. M. Timpe, Z. Stamatakis, A. Jennings et al., “Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies,” Hepatology, vol. 47, no. 1, pp. 17–24, 2008.

F. Ghasemi, S. Rostami, and Z. Meshkat, “Progress in the development of vaccines for hepatitis C virus infection,” World Journal of Gastroenterology, vol. 21, no. 42, pp. 11984–12002, 2015.

L. Mailly, E. Robinet, P. Meuleman, T. F. Baumert, and M. B. Zeisel, “Hepatitis C virus infection and related liver disease: the quest for the best animal model,” Frontiers in Microbiology, vol. 4, article 213, 2013.
[151] N. Nagpal, S. Goyal, D. Wahi et al., "Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease," Gene, vol. 570, no. 1, pp. 115–121, 2015.

[152] S. Larrat, S. Vallet, S. David-Tchouda et al., "Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin," Journal of Clinical Microbiology, vol. 53, no. 7, pp. 2195–2202, 2015.

[153] T. Ruggiero, A. Proietti, L. Boglione et al., "Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience," Archives of Virology, vol. 160, no. 11, pp. 2881–2885, 2015.

[154] S. Paolucci, L. Fiorina, B. Mariani et al., "Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients," Virology Journal, vol. 10, article 355, 2013.

[155] V. Cento, C. Mirabelli, R. Salpini et al., "HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors," PLoS ONE, vol. 7, article e39652, 2012.

[156] C. Sarrazin, H. Dvory-Sobol, E. Svarovskaia et al., "Baseline E.J. Lawitz, D. Gruener, J. M. Hillett et al., "A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C," Journal of Hepatology, vol. 57, no. 1, pp. 24–31, 2012.

[157] K. M. Kittrinos, D. Wyles, H. Dvory-Sobol, A. Worth, B. Han, and D. Brainard, "Evaluation of the resistance profile of ledipasvir, a nonstructural protein 5A inhibitor, in genotype 1 chronically infected HCV subjects treated with ledipasvir-containing regimens without sofosbuvir," Hepatology, vol. 60, pp. 1143a–1144a, 2014.

[158] Z. Plaza, V. Soriano, E. Vispo et al., "Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor," Antiviral Therapy, vol. 17, no. 5, pp. 921–926, 2012.

[159] R. Liu, S. Curry, P. McMonagle et al., "Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir," Antimicrobial Agents and Chemotherapy, vol. 59, no. 11, pp. 6922–6929, 2015.

[160] C. Premoli and A. Aghemo, "Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant-associated variants," Minerva Gastroenterologica e Dietologica, vol. 62, no. 1, pp. 76–87, 2016.

[161] R. A. Fridell, C. Wang, J.-H. Sun et al., "Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations," Hepatology, vol. 54, no. 6, pp. 1924–1935, 2011.

[162] E. J. Lawitz, D. Gruner, J. M. Hill et al., "A phase I, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C," Journal of Hepatology, vol. 57, no. 1, pp. 24–31, 2012.

[163] L. Cuypers, G. Li, P. Libin, S. Piamponsant, A.-M. Vandamme, and K. Theys, "Genetic diversity and selective pressure in hepatitis C virus genotypes 1–6: significance for direct-acting antiviral treatment and drug resistance," Viruses, vol. 7, no. 9, pp. 5018–5039, 2015.

[164] S. Nakamoto, T. Kanda, S. Wu, H. Shirasawa, and O. Yokosuka, "Hepatitis C virus NS5A inhibitors and drug resistance mutations," World Journal of Gastroenterology, vol. 20, no. 11, pp. 2902–2912, 2014.

[165] P. Krishnan, R. Tripathi, G. Schnell, T. Reisch, J. Beyer, and M. Irvin, "Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials," Hepatology, vol. 60, no. 1, pp. 1134a–1135a, 2014.

[166] C. Wang, L. Jia, H. Huang et al., "In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A," Antimicrobial Agents and Chemotherapy, vol. 56, no. 3, pp. 1588–1590, 2012.

[167] D. Hernandez, N. Zhou, J. Ueland, A. Monikowski, and F. McPhee, "Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors," Journal of Clinical Virology, vol. 57, no. 1, pp. 13–18, 2013.

[168] F. McPhee, J. Friborg, S. Levine et al., "Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir," Antimicrobial Agents and Chemotherapy, vol. 56, no. 7, pp. 3670–3681, 2012.

[169] Y. Karino, J. Toyota, K. Ikeda et al., "Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir," Journal of Hepatology, vol. 58, no. 4, pp. 646–654, 2013.

[170] F. McPhee, D. Hernandez, N. Zhou et al., "Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b," Antiviral Therapy, vol. 19, no. 5, pp. 479–490, 2014.

[171] J. Itakura, M. Kurosaki, H. Takada et al., "Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy," Hepatology Research, vol. 45, no. 10, pp. E115–E121, 2015.

[172] Y. Kai, H. Hikita, T. Tatsumi et al., "Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice," Journal of Gastroenterology, vol. 50, no. 11, pp. 1145–1151, 2015.

[173] C. Wang, L. Jia, D. R. O’Boyle II et al., "Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: Implications for cross-genotype activity," Antimicrobial Agents and Chemotherapy, vol. 58, no. 9, pp. 5155–5163, 2014.

[174] I. Lindström, M. Kjellin, N. Palanisamy et al., "Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naïve patients with hepatitis C virus genotypes 1a and 3a in Sweden," Infectious Diseases, vol. 47, no. 8, pp. 555–562, 2015.

[175] F. Poordad, C. Hezode, R. Trinh et al., "ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis," The New England Journal of Medicine, vol. 370, no. 21, pp. 1973–1982, 2014.

[176] E. S. Svarovskaia, H. Dvory Sobol, N. Parkin et al., "Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials," Clinical Infectious Diseases, vol. 59, no. 12, pp. 1666–1674, 2014.

[177] S. Zeuzem, G. M. Dusheiko, R. Salupere et al., "Sofosbuvir and ribavirin in HCV genotypes 2 and 3," The New England Journal of Medicine, vol. 370, no. 21, pp. 1993–2001, 2014.

[178] M. Charlton, E. Gane, M. P. Manns et al., "Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation," Gastroenterology, vol. 148, no. 1, pp. 108–117, 2015.
[179] X. Tong, S. Le Pogam, L. Li et al., “In vivo emergence of a novel mutant L159F/L320I in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir,” *Journal of Infectious Diseases*, vol. 209, no. 5, pp. 668–675, 2014.

[180] S. Chopp, R. Vanderwall, A. Hult, and M. Klepser, “Simeprevir and sofosbuvir for treatment of hepatitis C infection,” *American Journal of Health-System Pharmacy*, vol. 72, no. 17, pp. 1445–1455, 2015.

[181] V. C. Di Maio, V. Cento, C. Mirabelli et al., “Hepatitis C virus genetic variability and the presence of ns5b resistance-Associated mutations as natural polymorphisms in selected genotypes could affect the response to ns5b inhibitors,” *Antimicrobial Agents and Chemotherapy*, vol. 58, no. 5, pp. 2781–2797, 2014.

[182] P. Krishnan, R. Tripathi, M. Irvin et al., “P1230 lack of impact of baseline resistance-associated variants (RAVS) on treatment outcome in the aviator study with ABT-450/R, ABT-333 AND ABT-267, +/- Ribavirin,” *Journal of Hepatology*, vol. 60, no. 1, article S498, 2014.